Fused Or Hybrid Cells Patents (Class 435/70.2)
-
Patent number: 11008386Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: June 14, 2017Date of Patent: May 18, 2021Assignee: Rinat Neuroscience Corp.Inventors: Jaume Pons, Arnon Rosenthal
-
Patent number: 9504702Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.Type: GrantFiled: August 5, 2011Date of Patent: November 29, 2016Assignee: Seattle Genetics, Inc.Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
-
Patent number: 9498530Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: July 19, 2013Date of Patent: November 22, 2016Assignee: RINAT NEUROSCIENCE CORP.Inventors: Arnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
-
Patent number: 9005923Abstract: The present invention relates to yeast species which are normally capable of producing sophorolipids but which are modified in such way that they are incapable producing the latter compounds. These sophorolipid-negative strains surprisingly display equal growth characteristics and biomass formation as their wild type counterparts and are hence useful for the production of compounds such as recombinant proteins, glycolipids, polyhydroxyalkanoates and carotenoides. In addition, the present invention discloses two glucosyltransferase genes with key-functions in sophorolipid production.Type: GrantFiled: June 10, 2011Date of Patent: April 14, 2015Assignee: Universiteit GentInventors: Wim Soetaert, Sofie De Maeseneire, Karen Saerens, Sophie Roelants, Inge Van Bogaert
-
Patent number: 8969529Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: January 21, 2010Date of Patent: March 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Patent number: 8968736Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.Type: GrantFiled: August 21, 2013Date of Patent: March 3, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
-
Patent number: 8945874Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 13, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8945867Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.Type: GrantFiled: February 2, 2009Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
-
Patent number: 8945870Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: August 13, 2012Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Publication number: 20140248261Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: ApplicationFiled: September 9, 2011Publication date: September 4, 2014Applicants: NATIONAL CANCER CENTER, TRANS GENIC INC.Inventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Publication number: 20140193855Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.Type: ApplicationFiled: February 27, 2014Publication date: July 10, 2014Applicants: Veri-Q, Inc., North Carolina State UniversityInventors: Paul F. Agris, Christopher D.J. Pearce, Lloyd G. Mitchell
-
Patent number: 8759029Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.Type: GrantFiled: August 31, 2006Date of Patent: June 24, 2014Assignee: Universite LavalInventors: Jean-Pierre Julien, Makoto Urushitani
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Patent number: 8734794Abstract: A fully humanized antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.Type: GrantFiled: July 6, 2010Date of Patent: May 27, 2014Assignee: Opsona Therapeutics LimitedInventor: Jerome Dellacasagrande
-
Publication number: 20140087423Abstract: The present invention relates to a method of controlling quality and quantity of posttranslational modification of a recombinantly produced polypeptide/protein (glycoprotein), wherein the posttranslational modification affects the glycosylation profile and/or the acidic variants profile, as manifested in CEX profiles, wherein the polypeptide/protein (glycoprotein) production is in eukaryotic host cells, the method comprising the following steps: a) cultivating the eukaryotic cells in a suitable medium under conditions which allow the expression of the polypeptide/protein, wherein the content of the dissolved CO2 (pCO2) in the medium is at a first value during the initial growth phase of the eukaryotic cells, allowing the eukaryotic cells to grow, and b) increasing or decreasing the content of the dissolved CO2 (pCO2) in the medium during the production phase of the eukaryotic cells to a second value.Type: ApplicationFiled: April 12, 2012Publication date: March 27, 2014Applicant: LEK PHARMACEUTICALS D.D.Inventors: Matjaz Koncilja, Vatroslav Spudic, Sasa Stojkovic, Matjaz Tisu
-
Publication number: 20140037624Abstract: The invention provides anti-FGFR4 antibodies and methods of using the same.Type: ApplicationFiled: October 4, 2013Publication date: February 6, 2014Applicant: GENENTECH, INC.Inventors: Mark Dennis, Luc Desnoyer, Dorothy French
-
Patent number: 8632779Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: March 14, 2012Date of Patent: January 21, 2014Assignee: Absynth Biologics LimitedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Patent number: 8623353Abstract: The present invention is directed to a cross-reactive antibody that specifically inhibits or blocks mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of such an antibody. Also provided is a pharmaceutical composition comprising such an antibody, or a nucleic acid or vector encoding it. Further provided are methods of use of such compositions in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.Type: GrantFiled: September 23, 2004Date of Patent: January 7, 2014Assignees: Technische Universitat Munchen, Amgen Inc.Inventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
-
Publication number: 20130330323Abstract: In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.Type: ApplicationFiled: August 31, 2011Publication date: December 12, 2013Inventors: Robert J. Dunn, Marilyn R. Kehry
-
Publication number: 20130323790Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.Type: ApplicationFiled: July 18, 2013Publication date: December 5, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
-
Patent number: 8574580Abstract: Method for generating monoclonal antibodies that recognize progenitor cells. Said method comprises immunization of an Armenian hamster with neurospheres obtained from olfactory bulb cells from a 13.5-day mouse embryo and subsequent selection of the antibodies by means of neurosphere flow cytometry in the presence of propidium iodide. The antibodies thus obtained may be of use in the enrichment of cell cultures in progenitor cells, primarily neural progenitor cells.Type: GrantFiled: April 29, 2009Date of Patent: November 5, 2013Assignee: Consejo Superior de Investigaciones CientíficasInventors: Augusto Silva Gonzalez, Ignacio Del Valle Torres, Leyre García Benzaquen
-
Publication number: 20130224211Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.Type: ApplicationFiled: August 25, 2011Publication date: August 29, 2013Applicant: President and Fellows of Harvard CollegeInventors: Jose A Halperin, Michael Chorev
-
Patent number: 8486401Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.Type: GrantFiled: September 11, 2009Date of Patent: July 16, 2013Assignee: Lay Line Genomics S.p.A.Inventor: Michal M. Novak
-
Patent number: 8487081Abstract: The present invention relates to antigen-binding proteins having specificity for hepcidin, and their use for treating and diagnosing diseases associated with hepcidin.Type: GrantFiled: October 2, 2008Date of Patent: July 16, 2013Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique-CNRSInventors: Sophie Vaulont, Hugues Gascan, Josy Froger
-
Patent number: 8481290Abstract: An antibody specific for a chondroitin sulphate epitope is described, as is a hybridoma cell line which produces such an antibody. The antibody is useful in the diagnosis and treatment of connective tissue diseases, such as arthritis and sarcomas. Test kits and pharmaceutical compositions are also described.Type: GrantFiled: June 1, 2005Date of Patent: July 9, 2013Assignees: The National Research Council of Thailand, The Thailand Research Fund, Chiang Mai University of ThailandInventors: Prachya Kongtawelert, Tim Hardingham, Siriwan Ong-Chai, Kazuyuki Sugahara, Peraphan Pothacharoen, Nattachai Tiengburanathum
-
Publication number: 20130071951Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.Type: ApplicationFiled: November 6, 2012Publication date: March 21, 2013Inventors: Paul F. Agris, Christipher D.J. Pearce, Lloyd G. Mitchell
-
Publication number: 20130065254Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: VICTORIA V. LUNYAK
-
Patent number: 8394375Abstract: Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the A?1-40 peptide. Peptides with similar structural features and bind to the amyloid form of A?1-40 but not to monomeric A?1-40, are provided. Such peptides are useful as carrier molecules to deliver therapeutic and diagnostic reagents to amyloid plaques.Type: GrantFiled: April 22, 2010Date of Patent: March 12, 2013Assignee: The Regents of the University of CaliforniaInventor: Paul Taylor Martin
-
Publication number: 20120301894Abstract: Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.Type: ApplicationFiled: February 17, 2012Publication date: November 29, 2012Applicant: Life Technologies CorporationInventors: Brian AGNEW, Kyle R. Gee, Tamara G. Nyberg
-
Publication number: 20120269814Abstract: The present invention provides compositions and methods utilizing antagonistic antibodies which specifically bind to human c-MPL (e.g., TPO-R).Type: ApplicationFiled: November 10, 2010Publication date: October 25, 2012Applicant: AMGEN INC.Inventors: Ping Wei, Aaron George Winters, Christina Abbott
-
Publication number: 20120263724Abstract: Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle infection were identified. These proteins, mapped to the backbone, O-islands (OIs) and pO157. Because these-proteins are expressed during infection, and might help pathogens adapt to and counter hostile in vivo environments, those proteins identified in this study are useful as targets for drug and vaccine development. Also, such proteins are useful as markers of 0157 infection in stool specimens. Also described are methods of identifying immunogenic proteins.Type: ApplicationFiled: April 20, 2006Publication date: October 18, 2012Inventors: Manohar John, Indira T. Kudva, Stephen B. Calderwood, Bryan Krastins, David A. Sarracino
-
Patent number: 8278424Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: April 26, 2011Date of Patent: October 2, 2012Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20120231006Abstract: Disclosed is an isolated antigen binding proteins, such as but not limited to, an antibody or antibody fragment, that specifically bind to SEQ ID NO: 4, the amino acid sequence of extracellular loop 2 (ECL2) of human Orai1. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors and host cells useful in methods of making it, and methods of using it in treating disorders or diseases in patients.Type: ApplicationFiled: November 19, 2010Publication date: September 13, 2012Applicant: Amgen Inc.Inventors: Hung Q. Nguyen, Fen-Fen Lin, Xiao-juan Bi, Helen J. McBride, Shaw-Fen Sylvia Hu
-
Publication number: 20120189633Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.Type: ApplicationFiled: January 25, 2012Publication date: July 26, 2012Applicant: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
-
Publication number: 20120183597Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: October 4, 2011Publication date: July 19, 2012Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
-
Publication number: 20120151611Abstract: The present invention aims to provide a method for antibody preparation. The present invention is directed to a method for preparing an antibody-producing cell, which comprises the following steps: (1) transplanting metastatic cancer cells capable of expressing a target antigen into a non-human animal to ensure engraftment of the cancer cells in the animal; (2) immunizing the animal with the target antigen; and (3) collecting the antibody-producing cell from the immunized animal; as well as a method for preparing an antibody, which comprises collecting the antibody from the antibody-producing cell prepared by the above method.Type: ApplicationFiled: August 24, 2011Publication date: June 14, 2012Inventors: Hiroyuki Satofuka, Masahiro Uchino, Shingo Hanaoka
-
Patent number: 8163288Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: June 29, 2010Date of Patent: April 24, 2012Assignee: Absynth Biologics LimitedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Publication number: 20110318357Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: ApplicationFiled: January 21, 2010Publication date: December 29, 2011Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Patent number: 8062867Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: April 6, 2010Date of Patent: November 22, 2011Assignee: Epitomics, Inc.Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Publication number: 20110275063Abstract: The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be se according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet.Type: ApplicationFiled: July 10, 2009Publication date: November 10, 2011Applicant: President and Fellows of Harvard CollegeInventors: David A. Weitz, John Heyman
-
Publication number: 20110256153Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: March 11, 2011Publication date: October 20, 2011Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
-
Publication number: 20110236931Abstract: Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.Type: ApplicationFiled: April 14, 2009Publication date: September 29, 2011Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTEInventors: John R. Cashman, Mary T. MacDonald
-
Publication number: 20110207171Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.Type: ApplicationFiled: January 14, 2011Publication date: August 25, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian Agnew, Schuyler B. CORRY, Kyle R. GEE
-
Patent number: 7989171Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.Type: GrantFiled: February 16, 2005Date of Patent: August 2, 2011Assignee: Tecnogen S.C.P.A.Inventors: Rita De Santis, Angela Pelliccia, Giovanna Palombo, Paolo Carminati
-
Publication number: 20110158988Abstract: The present invention relates to an affinity ligand capable of selective interaction with a subset consisting of 37 consecutive amino acid residues or less from extracellular domains 2 and 3 of HER2, wherein the subset comprises the amino acid sequence LQVF and/or ESFDGD1 and to polypeptides consisting of such subsets.Type: ApplicationFiled: December 12, 2008Publication date: June 30, 2011Applicant: ATLAS THERAPEUTICS ABInventors: Mathias Uhlen, Johan Rockberg
-
Patent number: 7932048Abstract: The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the ?-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the ?-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the ?-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.Type: GrantFiled: March 9, 2006Date of Patent: April 26, 2011Assignee: Consejo Superior de Investigaciones CientificasInventor: Enrique Mendez
-
Publication number: 20110091494Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S.Type: ApplicationFiled: March 17, 2009Publication date: April 21, 2011Applicant: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
-
Publication number: 20110014117Abstract: The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.Type: ApplicationFiled: June 25, 2008Publication date: January 20, 2011Inventors: Yan Wang, Jonathan A. Pachter, Judith Anne Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Mary Diane Feingersh
-
Publication number: 20100285027Abstract: The present invention relates to antigen-binding proteins having specificity for hepcidin, and their use for treating and diagnosing diseases associated with hepcidin.Type: ApplicationFiled: October 2, 2008Publication date: November 11, 2010Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Sophie Vaulont, Hugues Gascan, Josy Froger